Isovue in Peripheral Digital Subtraction Angiography (DSA)

A Phase IV Multi-Center Study to Compare ISOVUE -250 and VISIPAQUE 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA)

No significant differences is expected in observed motion artifacts, heat or pain reported during peripheral DSA performed for diagnostic and/or endovascular therapeutic purposes.

Inclusion Criteria:

• provides written informed consent;
• at least 18 years of age;
• scheduled to undergo peripheral DSA for the diagnosis and/or treatment of PAOD

Exclusion Criteria:

• pregnant or lactating female;
• known allergies to one more more ingredients in wither product;
• history of severe congestive heart failure (Class IV);
• previously enrolled or received an investigational compound within 30 days;
• history of hypersensitivity to iodinated contrast agents;
• renal impairment eGFR <60 mL/min/1.73m2, calculated using the MDRD study equation
• any other medical condition decreasing chances of obtaining reliable data